Convalescent plasma as additional therapies in COVID-19 patients
Main Article Content
Keywords
COVID-19, convalescent plasma, additional therapy
Abstract
Corona Virus 2 (SARS-CoV-2) is a new virus who can make an infectious disease that we called Corona Virus Disease 2019 (COVID-19). The main symptoms manifest in the respiratory tract such as fever, cough, and shortness of breath. This disease spread very fast to various continents in a short time. The use of convalescent plasma as additional therapy for COVID-19 patients based on the previous cases like SARS, Ebola, MERS. A lot of research has been done to find the good therapy for patients. One of the approved treatments by WHO is the administration of COVID convalescent plasma (CCP), as additional therapy, to prevent cytokine storms and to increase life expectancy at COVID-19 patients in Indonesia. Plasma from healthy patients after having cured from COVID-19 infection, who has many Immunoglobulin G, processed by plasmapheresis. This review explained 299 plasma convalescent donors in the Jakarta Blood Center, Red Cross Indonesia. While for the efficacy of patients in the hospital there is no data that we can report. Some clinicians suggest that convalescent plasma should be administered immediately after infection, before the seventh day.
References
2. Pranata S, Vranada A, Armiyati Y, Samiasih A, Aisah S. Inflammatory markers for predicting severity , mortality , and need for intensive care treatments of a patient infected with covid-19 : a scoping review. Bali Med J. 2023;12(1):324–30.
3. World Health Organization. Coronavirus Disease2019 (COVID-19) [Internet]. Geneva; 2020. Available from: https://www.who.int/docs/default-source/searo/indonesia/covid19/who-situation-report-16.pdf?sfvrsn=d62ba9b1_2
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020;395(10223):507–13.
6. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. Available from: http://dx.doi.org/10.1016/S1473-3099(20)30141-9
7. Kementrian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Jakarta; 2020.
8. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Geneva; 2020.
9. Mire CE, Geisbert JB, Agans KN, Thi EP, Lee ACH, Fenton KA, et al. Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis. 2016;214(suppl 3):S367–74.
10. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323(16):1582–9.
11. Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MI, Patel SK, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob. 2020;19(1):40.
12. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–6.
13. Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2005;24(1):44–6.
14. Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2004;10(7):676–8.
15. Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–8.
16. Unit Donor Darah Pusat Palang Merah Indonesia. Protokol Penyiapan Plasma Konvalesen untuk Terapi COVID-19 di Unit Donor Darah Palang Merah Indonesia. Jakarta; 2020.
17. Malani AN, Sherbeck JP, Malani PN. Convalescent Plasma and COVID-19. JAMA - J Am Med Assoc. 2020;324(5):524.
18. Badan Pengawas Obat dan Makanan. Rekomendasi tentang Pengawasan Pemanfaatan Plasma Konvalesen dan Imunoglobulin Konsentrat dalam Terapi COVID-19 dan Petunjuk Teknis Penjaminan Mutu Pengolahan Plasma Konvalesen COVID-19. Jakarta; 2020.
19. Kementrian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan (PMK) Republik Indonesia Nomor 91 tahun 2015 tentang Standar Pelayanan Transfusi Darah. Jakarta; 2015.
20. Badan Pengawas Obat dan Makanan. Peraturan BPOM No. 10 Tahun 2017 tentang Penerapan Pedoman Cara Pembuatan Obat Yang Baik di Unit Transfusi Darah Dan Pusat Plasmaferesis. Jakarta; 2017.
21. Unit Donor Darah Palang Merah Provinsi DKI Jakarta (UDD PMI). Laporan penyediaan plasma konvalesen 14 Juni – 14 Oktober 2020. Jakarta; 2020.